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Abstract
Background: Bisphosphonates possess strong affinity to bone.
99mTc bisphosphonate complexes are widely used
for bone scintigraphy. For positron emission tomography (PET) bone imaging, Ga-68-based PET tracers based on
bisphosphonates are highly desirable.
Findings: Two trimeric bisphosphonate conjugates of the triazacyclononane-phosphinate (TRAP) chelator were
synthesized, labeled with Ga-68, and used for microPET imaging of bone in male Lewis rats. Both Ga-68 tracers
show bone uptake and, thus, are suitable for PET bone imaging. Surprisingly, Ga-71 nuclear magnetic resonance
data prove that Ga(III) is not located in the chelating cavity of TRAP and must therefore be bound by the
conjugated bisphosphonate units.
Conclusion: The intrinsic Ga-68 chelating properties of TRAP are not needed for Ga-68 PET bone imaging with
TRAP-bisphosphonate conjugates. Here, TRAP serves only as a trimeric scaffold. For preparation of Ga-68-based
bone seekers for PET, it appears sufficient to equip branched scaffolds with multiple bisphosphonate units, which
serve both Ga-68-binding and bone-targeting purposes.
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Background
Geminal bisphosphonates possess strong affinity to bone
[1,2]. In living organisms, administration of bisphospho-
n a t e sl e a d st oi n h i b i t i o no fo steoclasts (bone resorbing
cells), which results in a lower rate of bone resorption
[3,4]. Therapy with bisphosphonate drugs is thus per-
formed to prevent decrease of bone density caused by
osteogenesis imperfecta (brittle bone disease) [5] or
osteoporosis [3,6]. In addition, bisphosphonate com-
plexes of
99mTc (e.g., of medronic acid, ‘
99mTc-MDP’;
see Figure 1) are the mainstay of bone imaging by scin-
tigraphy and SPECT. However, as positron emission
tomography (PET) offers higher resolution and sensitiv-
ity, PET bone-imaging agents are of high interest. Direct
utilization of the b
+-emitting radionuclide
18 F( t1/2 =
110 min, Emax,b+ = 634 keV) is the most simple and
straightforward approach because [
18 F]fluoride
18 F
-
inherently possesses a high affinity to bone. However,
18
F is cyclotron-produced, and therefore, a full geographi-
cal coverage, comparable to the supply of generator-pro-
duced
99mTc, cannot be guaranteed. Thus,
bisphosphonate mono-conjugates of the currently most
popular radiometal chelators 1,4,7,10-tetraazacyclodode-
cane-tetraacetic acid [7-9] and 1,4,7-triazacyclononane-
triacetic acid [10] have been prepared to utilize genera-
tor-produced
68 Ga (t1/2 =6 8m i n ,Emax,b+ =1 . 9M e V )
for PET bone imaging. Advancing this approach, this
pilot study describes preclinical PET imaging results for
trimeric bisphosphonate conjugates of the recently
introduced chelator triazacyclononane-phosphinate
(TRAP) (see Figure 2) [11-13].
* Correspondence: johannes.notni@tum.de
1Pharmaceutical Radiochemistry, Technische Universität München, Walther-
Meissner-Str. 3, Garching 85748, Germany
Full list of author information is available at the end of the article
Notni et al. EJNMMI Research 2012, 2:13
http://www.ejnmmires.com/content/2/1/13
© 2012 Notni et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.Methods
General procedures and instrumentation (nuclear mag-
netic resonance (NMR), electrospray mass spectroscopy
(ESI-MS), ultrafiltration/diafiltration, PET) have been
described before [13]. [
18 F]fluoride formulation for
injection was prepared by adding 100 MBq of
18 F
(obtained from routine cyclotron production at Klini-
kum rechts der Isar, Technische Universität München,
München, Germany) to phosphate buffered saline (PBS)
(1 mL).
Synthesis of bisphosphonate conjugates (Figure 2):
TRAP·2H2O (0.3 mmol, 185 mg), diisopropylethylamide
(3 mmol, 388 mg, 510 μL), and the amino-bisphospho-
nate (1.5 mmol); for TRAP(MDP)3, tetraethyl(amino-
methylene)bisphosphonate 455 mg; and for TRAP(PDP)
3, tetraethyl(1-aminopropylene)bisphosphonate 500 mg,
were dissolved in DMSO (2 mL). Then, HATU (2.4
mmol, 921 mg) was added with stirring. After 25 min,
the reaction mixture was diluted with water (50 mL)
and subjected to diafiltration (membrane with 500 Da
MWCO). After 250 mL of water had passed, the cell
content was concentrated in vacuo and subjected to pre-
parative HPLC (column: YMC C18 ec 250 × 30 mm;
detection wavelength, 220 nm; eluent A, MeCN with
0.1% TFA; eluent B, water with 0.1% TFA; gradient 25%
to 50% B in 20 min, tR(dodecaethyl-TRAP(MDP)3)=1 2
min, tR(dodecaethyl-TRAP(PDP)3) = 16 min). After eva-
poration of the solvents, the remaining viscous oil was
dissolved in HBr/glacial acetic acid (33%) and stirred for
3 days. Addition of methanol to the reaction mixture
yielded the products as colorless, crystalline solids. Data
for TRAP(MDP)3: yield 201 mg (61%); MW (calculated
for C21H51N6O27P9) 1,098.43; ESI-MS negative m/z =
1,097 (M-H
+)a n d5 4 8( M - 2H
+);
1 H NMR (600 MHz,
D2O) δ = 2.13 (m, 6 H), 2.67 (m, 6 H), 3.48 (d,
3JHH =
5 . 4H z ,6H ) ,3 . 5 6( s ,b r o a d ,1 2H ) ,a n d4 . 7 1( t ,JPH =
21.3 Hz, 3 H) ppm;
13 CN M R( 1 5 1M H z ,D 2O) δ =
26.11 (d,
1JPC = 93.18 Hz), 28.65, 52.13, 54.74 (d,
1JPC =
89.07 Hz), 47.45 (t,
1JPC = 139.28 Hz), and 174.54 (dt,
2JPC = 12.28 and
3JPC =4 . 3 4H z )p p m ;a n d
31PN M R
(121 MHz, D2O) δ = 14.10 (d,
2JPP = 15.7 Hz) and 39.90
ppm. Data for TRAP(PDP)3: yield 195 mg (55%); MW
(calculated for C27H63N6O27P9) 1,182.59; ESI-MS nega-
tive m/z = 1,181 (M-H
+), 590 (M-2 H
+), and 393 (M-3
H
+);
1 H NMR (600 MHz, D2O) δ =2 . 0 7( m ,6H ) ,2 . 1 0
(m, 6 H), 2.36 (tt, JPH =2 3 . 5 2H z ,
3JHH = 5.97 Hz, 3 H),
2.53 (m, 6 H), 3.44 (t,
3JHH =6 . 3H z ,6H ) ,3 . 4 5( t ,
broad,
3JHH = 6.6 Hz), and 3.52 (s, broad, 12 H) ppm;
13
C NMR (151 MHz, D2O) δ = 25.36 (t,
2JPC =4 . 2H z ) ,
26.29 (d,
1JPC = 93.5 Hz), 28.63 (d,
2JPC = 3.9 Hz), 35.77
(t,
1JPC = 128.5 Hz), 39.48 (d,
3JPC = 7.4 Hz), 52.14,
54.82 (d,
1JPC = 88.6 Hz), and 175.41 (d,
3JPC = 13.1 Hz)
ppm; and
31P NMR (121 MHz, D2O) δ = 21.53 (d,
2JPP
= 15.5 Hz) and 39.69 ppm.
68 Ga for labeling was obtained from a SnO2-based
68Ge/
68 Ga generator (iThemba LABS, Somerset West,
South Africa), eluted with 1.0 M HCl. A 1.25 mL fraction
of the eluate containing ca. 80% of the total activity (ca.
1.3 GBq) was adjusted to pH 3.3 by adding a solution of
600 mg 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfo-
nic acid (HEPES) in 0.5 mL water. To a 90 μLa l i q u o to f
this mixture, 10 μLo f1 0
-4 M stock solution of the ligand
was added. After heating for 5 min to 95°C, the solution
was passed over a cation exchanger SPE cartridge (Chro-
mafix HR-XC M, Macherey-Nagel, Düren, Germany) and
purged with water (1 mL). This procedure removed non-
complexed
68 Ga as well as HEPES, which was confirmed
by processing of blank samples. Radiochemical yields,
determined by measuring the activity on the cartridge and
in the eluate, were > 85%. Formulation was done by
adjusting the pH of the eluate to 7.4 by adding approxi-
mately 50 μL of a solution of NaOH (1 g) and NaH2PO4
(483 mg) in water (20 mL) while monitoring the pH with
a pH meter. ‘Free’
68 Ga formulation was prepared by
addition of the generator eluate (40 μL, ca.5 0M B q )t o
PBS (1 mL), resulting in pH 7.2.
All animal experiments were carried out in accordance
with the current animal welfare regulations in Germany.
Figure 1 Examples for common bisphosphonate drugs.
Figure 2 Synthesis of trimeric TRAP-bisphosphonate conjugates TRAP(MDP)3 and TRAP(PDP)3.
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under standard laboratory conditions (12 h light/12 h
dark) and given standard diet and water ad libitum.F o r
PET, ca. 35 MBq of tracer was injected into the tail vein
under isoflurane anesthesia. Two subsequent scans of 15
min were recorded 60 min post injection, using two dif-
ferent axial bed positions in order to image the entire
animals. Images were reconstructed using a OSEM3D
algorithm without scatter and attenuation correction.
For each full-body maximum intensity projection (MIP),
two part-body MIPs were stitched together manually
using graphics software. PET images are from represen-
tative animals reflecting the group.
Results and discussion
Figure 3 shows that free
68 Ga(III) (we use this general-
ized term since
68 Ga species in PBS solutions are not
well defined) provides almost no contrast of the skeleton
over other tissues, as intravenous injection of free
68 Ga
(III) predominantly results in transferrin-bound activity
[14-17]. In contrast, both bisphosphonate tracers
68 Ga-
TRAP(MDP)3 and
68 Ga-TRAP(PDP)3 bind to bone
while showing low levels in blood and soft tissues.
Apparently, PET image quality achieved therewith can-
not compete with that of [
18 F]fluoride.
18 F possesses a
lower positron energy than
68 Ga, resulting in lower tis-
sue penetration (FW20H of 0.54 mm and 2.12 mm in
soft tissue for
18 Fa n d
68 Ga, respectively [18]), and
therefore in a lower degree of image blurring. However,
a st h ed i f f e r e n c ei nr e s o l u t i o nf o rac l i n i c a l3 - m mP E T
camera is small (3.05 mm for
18 F and 3.57 mm for
68
Ga [18]), a successful application of
68 Ga bone-imaging
agents in patients is not precluded.
Upon investigation of the mode of gallium binding, we
found that an equimolar mixture of
69,71 Ga
3+ and either
68 Ga-TRAP(MDP)3 or
68 Ga-TRAP(PDP)3 does not
yield any signal in
71 Ga NMR spectra, not even after
heating to 95°C for hours. However, the octahedral
N3O3 coordination usually found for ‘in-cage’ Ga(III)
complexes of TRAP ligands generally yields sharp
71 Ga
NMR resonances at δ = 130 to 142 ppm [11,12].
Obviously, Ga(III) ion is not located in the TRAP cavity
and, therefore, must be complexed in an ‘out-of-cage’
manner by the bisphosphonate groups. Although this
result is quite unexpected, PET images nevertheless
prove that the degree of kinetic stability of these com-
plexes is sufficiently high to carry
68 Ga to the bone and
retain it there. However, Figure 3 also shows a slightly
higher background uptake for
68 Ga-TRAP(MDP)3, most
likely caused by partial decomplexation in vivo due to
lower complex stability. Clearance of both
68 Ga tracers
occurred faster than
18 F
- and exclusively via the
kidneys.
Conclusion
68 Ga-labeled trimeric bisphosphonate conjugates of
TRAP were successfully applied for bone imaging in
rats. Surprisingly,
71 Ga NMR investigation revealed that
Ga(III) ion is not located in the macrocyclic cavity of
TRAP and, therefore, must be complexed by one or
Figure 3 PET scans (MIP, 60 min p.i.) of Lewis rats using different tracers. (A) Free
68 Ga(III), (B)
68 Ga-TRAP(MDP)3,( C)
68 Ga-TRAP(PDP)3,
and (D)[
18 F]fluoride.
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chelation site of TRAP possesses excellent Ga(III) com-
plexing properties [12], it apparently cannot compete
with the bisphosphonates. In
68 Ga-TRAP(MDP)3 and
68
Ga-TRAP(PDP)3, TRAP thus merely serves as a scaffold,
and its ability for
68 Ga binding is not required. We
therefore conclude that in designing bisphosphonate tra-
cers for
68 Ga-based PET bone imaging, the introduction
of chelating moieties other than the bisphosphonates
themselves might be unnecessary. Rather, it appears to
be sufficient to equip suitable branched scaffolds with
multiple bisphosphonate units which serve both
68 Ga-
binding and bone-targeting purposes.
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